arrow
F

Fabio Stagno

University of Messina
H指数:38
被引数:5,279

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms

高危慢性期CML患者长期惰性临床病程且无细胞遗传学或分子学反应:一例挑战既定反应范式的病例

2026-08-100
OA
Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study

年龄和性别对慢性髓性白血病患者在一线治疗中分子反应的影响:一项意大利CML网络队列研究

2026-04-180
OAAI
Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs

靶向表达不同BCR::ABL1水平的白血病干细胞和祖细胞:asciminib单独或联合TKIs的抗白血病活性

2026-03-300
OAAI
Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation

Pierro, F.; Stella, S.; Fazio, M.; Russo, S.; Massimino, M.; Mirabile, G.; Belletti, D.; Allegra, A.; Stagno, F. 慢性粒细胞白血病和BCR::ABL1 T315I突变。Int. J. Mol. Sci. 2025, 26, 11285. [Google Scholar] [CrossRef]

2026-03-030
OAAI
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study
2026-01-110
OA
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50-60 Years: A Campus CML Study

基线特征、治疗选择及早期一线TKI永久停药在50-60岁新诊断慢性髓性白血病患者中的研究:一项Campus CML研究

BLOOD
IF23.1
2024-11-050
PRE